Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
deals
gene therapy
8
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
8
×
san diego top stories
san francisco blog main
san francisco top stories
startups
8
×
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cell therapy
alzheimer's disease
cancer immunotherapy
fda
gilead sciences
merck
arch venture partners
astrazeneca
bayer
clinical trials
What
bio
roundup
pfizer’s
amid
bombast
cancer
caught
coronavirus
debate
develop
discussion
drug
efforts
future
meso’s
miss
new
pandemic
presidential
promise
remains
response
today
tuesday’s
vaccine
viewers
acquisitions
ahead
aiming
albert
alzheimer’s
ambys
approval
asco
big
biggest
biogen’s
biopharmaceutical
biotech
bourla
Language
unset
unknown
Current search:
startups
×
" san diego blog main "
×
" gene therapy "
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?